NCT02679131 2019-11-20
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Acrotech Biopharma Inc.
Phase 1 Terminated
Acrotech Biopharma Inc.
Yale University
National Cancer Institute (NCI)